Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olverembatinib in Ph+ ALL
NCT05466175Phase 2Unknown
- Start
- Oct 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olverembatinib in acute lymphoblastic leukemia (ALL). Status: unknown.
02
Drugs
olverembatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05466175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05466175.